Arialys Therapeutics

Home Team News Careers Contact

News

« Back to News

September 12, 2023

Endpoints | Avalon's latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions

Arialys Therapeutics announced Tuesday that it tied the bow on a $58 million seed round to develop treatments specifically for brain disorders caused by immune reactions.

To read the full article, click here (subscription may be required).

Sign up for news updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Follow us

©2024 Arialys Therapeutics, 11099 North Torrey Pines Rd., Ste 290, La Jolla, CA 92037